stockrowLineage Cell Therapeutics, Inc.
LCTXLineage Cell Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.6 million, up 53.2% from fiscal 2024.
- Revenue
- −61.3%
- EPS
- +104.8%
- Free cash flow
- −32.4%
- Total debt
- −68.8%
Quarter to June 2026, against a year earlier
Follow LCTX
Alert me
Lineage Cell Therapeutics, Inc. (LCTX) Return on invested capital
Lineage Cell Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −186.8%, down 186.8 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −120.9% (fiscal 2015) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 45.86 |
| FY2024 | −45.9% | 12.21 |
| FY2023 | −58.1% | 41.44 |
| FY2022 | −99.5% | (5.08) |
| FY2021 | −94.4% | (63.59) |
| FY2020 | −30.8% | (0.70) |
| FY2019 | −30.1% | 12.26 |
| FY2018 | −42.4% | (23.14) |
| FY2017 | −19.3% | 14.47 |
| FY2016 | −33.7% | 87.12 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ARCT Arcturus Therapeutics Holdings Inc. compare | 0.00% |
| LRMR Larimar Therapeutics, Inc. compare | 0.00% |
| CAMP CAMP4 Therapeutics Corporation compare | 0.00% |
| QTTB Q32 Bio Inc. compare | 0.00% |
| SPRY ARS Pharmaceuticals, Inc. compare | 0.00% |
| RCKT Rocket Pharmaceuticals, Inc. compare | −114.7% |
| LCTX Lineage Cell Therapeutics, Inc. | −186.8% |
| LXEO Lexeo Therapeutics, Inc. compare | −253.5% |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)